Apnimed, Inc. Common Stock (APMD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Apnimed, Inc. Common Stock (APMD) has a cash flow conversion efficiency ratio of -0.077x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.81 Million) by net assets ($257.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. View Apnimed, Inc. Common Stock stock quote for real-time trading data and today's change.
Apnimed, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2024–2025)
This chart illustrates how Apnimed, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see Apnimed, Inc. Common Stock market cap and net worth for the company's overall valuation and market capitalisation.
Apnimed, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Apnimed, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see Apnimed, Inc. Common Stock (APMD) total assets for a full breakdown of the balance sheet.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SK Networks Co Ltd
KO:001740
|
0.165x |
|
Ategrity Specialty Insurance Company Holdings
NYSE:ASIC
|
0.066x |
|
Sinostone Guangdong Co Ltd
SHE:001212
|
0.011x |
|
Heritage Insurance Hldgs Inc
NYSE:HRTG
|
0.250x |
|
Gracell Biotechnologies Inc.
NASDAQ:GRCL
|
-0.039x |
|
HyUnion Holding Co Ltd
SHE:002537
|
0.017x |
|
Shenzhen United Winners Laser Co Ltd
SHG:688518
|
0.024x |
|
Fugro N.V.
AS:FUR
|
0.023x |
Annual Cash Flow Conversion Efficiency for Apnimed, Inc. Common Stock (2024–2025)
The table below shows the annual cash flow conversion efficiency of Apnimed, Inc. Common Stock from 2024 to 2025. Review Apnimed, Inc. Common Stock (APMD) financial flexibility to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-372.78 Million | $-77.83 Million | 0.209x | -52.90% |
| 2024-12-31 | $-248.62 Million | $-110.21 Million | 0.443x | -- |
About Apnimed, Inc. Common Stock
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in Ca… Read more